Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
С. Н. ТерещенкоNational Medical Research Center of Cardiology; Russian Academy of Postgraduate Medical EducationМ. В. ШестаковаФ. Т. АгеевNational Medical Research Center of CardiologyG. R. GalstyanА. S. GalyavichKazan State Medical UniversityМ. Г. ГлезерI.M. Sechenov First Moscow State Medical UniversityИ. В. ЖировNational Medical Research Center of Cardiology; Russian Academy of Postgraduate Medical EducationKarpov IuANational Medical Research Center of CardiologyZhanna KobalavaPeoples’ Friendship University of RussiaС.Т. МацкеплишвилиMedical Research and Educational Center. Moscow State University
2020en
ABI
Аннотация
Relationships and Activities. The Council of Experts was supported by AstraZeneca.
Ҳали таржима қилинмаган
Идентификаторлар
Иқтибослар ва манбалар
2 та иқтибос0 та фойдаланилган манба